162 related articles for article (PubMed ID: 17957467)
21. Punicic acid is an omega-5 fatty acid capable of inhibiting breast cancer proliferation.
Grossmann ME; Mizuno NK; Schuster T; Cleary MP
Int J Oncol; 2010 Feb; 36(2):421-6. PubMed ID: 20043077
[TBL] [Abstract][Full Text] [Related]
22. Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo.
Hsu YL; Kuo PL; Tzeng TF; Sung SC; Yen MH; Lin LT; Lin CC
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e290-9. PubMed ID: 18522681
[TBL] [Abstract][Full Text] [Related]
23. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
24. A peptide derived from alpha-fetoprotein inhibits the proliferation induced by estradiol in mammary tumor cells in culture.
Sierralta WD; Epuñan MJ; Reyes JM; Valladares LE; Andersen TT; Bennett JA; Jacobson HI; Pino AM
Oncol Rep; 2008 Jan; 19(1):229-35. PubMed ID: 18097600
[TBL] [Abstract][Full Text] [Related]
25. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.
Chen D; Cui QC; Yang H; Dou QP
Cancer Res; 2006 Nov; 66(21):10425-33. PubMed ID: 17079463
[TBL] [Abstract][Full Text] [Related]
26. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
27. Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction.
Liu XH; Zheng XF; Wang YL
Chin Med J (Engl); 2009 Jul; 122(14):1681-5. PubMed ID: 19719971
[TBL] [Abstract][Full Text] [Related]
28. Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules.
Nizamutdinova IT; Lee GW; Lee JS; Cho MK; Son KH; Jeon SJ; Kang SS; Kim YS; Lee JH; Seo HG; Chang KC; Kim HJ
Carcinogenesis; 2008 Oct; 29(10):1885-92. PubMed ID: 18586687
[TBL] [Abstract][Full Text] [Related]
29. A novel series of potent cytotoxic agents targeting G2/M phase of the cell cycle and demonstrating cell killing by apoptosis in human breast cancer cells.
Mandal S; Bérubé G; Asselin E; Mohammad I; Richardson VJ; Gupta A; Pramanik SK; Williams AL; Mandal SK
Bioorg Med Chem Lett; 2007 Sep; 17(17):4955-60. PubMed ID: 17596942
[TBL] [Abstract][Full Text] [Related]
30. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
31. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Hoke EM; Maylock CA; Shacter E
Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
[TBL] [Abstract][Full Text] [Related]
32. 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity.
Leese MP; Leblond B; Smith A; Newman SP; Di Fiore A; De Simone G; Supuran CT; Purohit A; Reed MJ; Potter BV
J Med Chem; 2006 Dec; 49(26):7683-96. PubMed ID: 17181151
[TBL] [Abstract][Full Text] [Related]
33. Neo-tanshinlactone inspired synthesis, in vitro evaluation of novel substituted benzocoumarin derivatives as potent anti-breast cancer agents.
Sashidhara KV; Rosaiah JN; Kumar M; Gara RK; Nayak LV; Srivastava K; Bid HK; Konwar R
Bioorg Med Chem Lett; 2010 Dec; 20(23):7127-31. PubMed ID: 20951035
[TBL] [Abstract][Full Text] [Related]
34. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of NF-kappaB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate.
Ma G; Tabanca N; Husnu Can Baser K; Kirimer N; Pasco DS; Khan IA; Khan SI
Cancer Chemother Pharmacol; 2009 Mar; 63(4):673-80. PubMed ID: 18597088
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells.
Lee YM; Ting CM; Cheng YK; Fan TP; Wong RN; Lung ML; Mak NK
Cancer Lett; 2008 Sep; 268(2):295-307. PubMed ID: 18492602
[TBL] [Abstract][Full Text] [Related]
37. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
[TBL] [Abstract][Full Text] [Related]
38. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
39. Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells.
Renoir JM; Bouclier C; Seguin A; Marsaud V; Sola B
J Mol Endocrinol; 2008 Mar; 40(3):101-12. PubMed ID: 18316469
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
Leese MP; Jourdan FL; Gaukroger K; Mahon MF; Newman SP; Foster PA; Stengel C; Regis-Lydi S; Ferrandis E; Di Fiore A; De Simone G; Supuran CT; Purohit A; Reed MJ; Potter BV
J Med Chem; 2008 Mar; 51(5):1295-308. PubMed ID: 18260615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
